


TCRs by Intelligent Design

Scott Cuthill
International Cancer Cluster Showcase
Boston, June 5th 2023
scott@etsembly.io

Non-confidential



Etceembly's place in the the evolving TCR therapy landscape





Etcembly is a T Cell Receptor discovery & engineering company

With EMLy™ we leverage the power of Generative AI to deliver optimal TCRs

EMLy™ combines:

3D structures

patient-derived and public TCR repertoire datasets

in-house sequences from our microfluidics platform




Novel platforms *in silico* for:

discovery of TCRs to disease targets

rapid engineering for improved TCR affinity and specificity



safety assessment of candidates

Etcmby engineered TCRs have potent and selective cellular activity



| TCR | EC50 | Kd by SPR | TCR expression % |
|------------------------------|--------|-------------|------------------|
| Etcmby; Parental TCR | 4.8 nM | 58 μ M | 53.4% |
| Etcmby; Affinity Matured TCR | 0.2 nM | 5.6 μ M | 51.2% |
| Etcmby; Non-target TCR | U/D | U/D | 58.2% |
| Competitor A; Target TCR | 6.6 nM | 55 μ M | 52.9% |
| Competitor B; Non-target TCR | U/D | N/A | 28.8% |

Engineered TCRs show enhanced cellular activity vs wt



Engineered TCRs only signal in cells expressing the relevant target antigen



EMLy™ can be used to discover and engineer TCRs for TCR-T cell therapy and soluble T cell engager applications

